MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 70,000 Shares of Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 70,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the sale, the chief executive officer directly owned 2,878,577 shares in the company, valued at $41,710,580.73. This trade represents a 2.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Da Silva Jorge Santos also recently made the following trade(s):

• On Monday, December 8th, Da Silva Jorge Santos sold 130,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00.

MoonLake Immunotherapeutics Trading Up 0.3%

Shares of MLTX stock traded up $0.04 during mid-day trading on Wednesday, hitting $14.59. The company’s stock had a trading volume of 1,293,485 shares, compared to its average volume of 1,743,358. The company has a market cap of $937.12 million, a PE ratio of -4.39 and a beta of 1.21. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The company’s fifty day simple moving average is $11.20 and its 200-day simple moving average is $36.25. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period last year, the business earned ($0.56) earnings per share. As a group, equities research analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of MoonLake Immunotherapeutics by 114.4% during the 1st quarter. US Bancorp DE now owns 2,208 shares of the company’s stock worth $86,000 after buying an additional 1,178 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of MoonLake Immunotherapeutics by 8.2% during the first quarter. PNC Financial Services Group Inc. now owns 9,200 shares of the company’s stock valued at $359,000 after acquiring an additional 700 shares during the last quarter. Nuveen LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the first quarter valued at approximately $26,308,000. Quarry LP bought a new stake in MoonLake Immunotherapeutics during the first quarter worth $94,000. Finally, Cubist Systematic Strategies LLC purchased a new position in MoonLake Immunotherapeutics in the first quarter worth $970,000. 93.85% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wedbush reduced their price objective on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating for the company in a research report on Tuesday, September 30th. The Goldman Sachs Group restated a “neutral” rating and issued a $7.00 price target on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 1st. Guggenheim decreased their price target on shares of MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 30th. BTIG Research lowered shares of MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a report on Monday, September 29th. Finally, Jefferies Financial Group cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective on the stock. in a research report on Monday, September 29th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $30.25.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.